NEW YORK (GenomeWeb) – Genomeon and Cloud Pharmaceuticals have signed an agreement to mine next-generation sequencing data to aid in drug development.

Under the terms of the agreement, Cloud Pharmaceuticals will be able to use Genomeon's microsatellite technology to find novel drug targets and companion biomarkers in NGS data.

Floyd, Virginia-based Genomeon analyzes short tandem repeat sequences, called microsatellites, which could serve as drug targets or biomarkers for diagnostic purposes.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.